As filed with the Securities and Exchange Commission on August 5, 2020
Registration No. 333-214077
Registration No. 333-220382
Registration No. 333-212851
Registration No. 333-206753
Registration No. 333-168331
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO.
333-214077
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM
S-8 REGISTRATION STATEMENT NO. 333-220382
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO.
333-212851
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM
S-8 REGISTRATION STATEMENT NO. 333-206753
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO.
333-168331
UNDER THE SECURITIES ACT OF 1933
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Exact name of registrant as specified in its charter)
|
|
|
Israel
|
|
Not Applicable
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
5 Basel Street
P.O. Box 3190
Petach
Tikva, 4951033 Israel
(Address of Principal Executive Offices)
Teva Pharmaceuticals USA, Inc.
400 Interpace Parkway
Building A, 4th Floor
Parsippany, NJ 07054
Attention: Deborah Griffin
(888) 838-2872
(Name, address and telephone number, including area code, of agent for service)
Copy to:
Ross M.
Leff, Esq.
Kirkland & Ellis LLP
601 Lexington Avenue
New
York, New York 10022-4675
(212) 466-4800
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company or an emerging growth company. See definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large Accelerated Filer
|
|
☒
|
|
Accelerated Filer
|
|
☐
|
|
|
|
|
Non-Accelerated Filer
|
|
☐
|
|
Smaller Reporting Company
|
|
☐
|
|
|
|
|
|
|
|
|
Emerging Growth Company
|
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐